An experimental drug has blocked the progression of prostate cancer in
an animal model with an aggressive form of the disease, new research
shows.
The agent, OSU-HDAC42, belongs to a new class of drugs called
histone deacetylase (HDAC) inhibitors, compounds designed to reactivate
genes that normally protect against cancer but are turned off by the
cancer process.
The study, conducted by the Ohio State University Comprehensive
Cancer Center researchers who also developed the drug, showed that the
agent kept mice with a precancerous condition from developing advanced
prostate cancer. Read More...